Divi's Laboratories Shares Rise to 52-Week High After Strong Q2 Earnings
Divi's Laboratories shares reached a fresh 52-week high following strong Q2 FY27 results, with net profit rising 64% year-on-year to Rs 1,127 crore and revenue increasing 35% to Rs 3,676 crore. Brokerages highlighted growth in custom synthesis and peptide manufacturing, with some raising target prices and maintaining positive ratings. While most brokerages remain optimistic about the company's expansion and earnings potential, a few noted limited upside at current valuations. The stock's gains also contributed to a rise in the Nifty Pharma index.
First-hand measurement across 10 sources
We measured how 10 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 34/100.
Outlets measured: businessstandard, moneycontrol, moneycontrol, moneycontrol, news18, economictimes, mint, economictimes, and 2 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 8 Nov, 05:25 am. Other outlets followed.